ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Sarcoidosis in hospitalised patients in Western Australia: A long-term study on prevalence, comorbidity and mortality.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine disease prevalence, comorbidity and mortality for hospitalised patients with sarcoidosis in Western Australia (WA).
methodsA retrospective statewide cohort study of patients over 15 years of age hospitalised with sarcoidosis between 1980 and 2014. Sarcoidosis was identified based on validated ICD -9CM/ICD10-AM based algorithms with index admission treated as baseline. Period and point prevalence per 100.000 adult population and mortality rate (MR) per 100 person years were estimated with 95% confidence intervals (CI). Kaplan Meyer survival curves and other outcomes were compared with a comparator group of Rheumatoid Arthritis patients with interstitial lung disease (RA-ILD). Median values are given with interquartile range (IQR).
resultsWe included 276 patients with sarcoidosis (index age 58 yrs IQR 46-69, 51.4 % females, invasive assessment in 68%) for a period prevalence of 21.1 (CI 18.7-23.7) and a 2015-point prevalence of 12.1 (CI 10.6-13.8). No specific risk factors were identified and extrapulmonary manifestations were recorded in 15%. During follow-up (3428-person years; median 11 years, IQR 5-19), patients with sarcoidosis were more likely to develop hypercalcemia (10.9 vs 4. 1%, p<0.01), new onset autoimmune rheumatic disease (9.3 vs 2.3%, p<0.01) and incident cancer (21.5 vs15%, p=0.07) and less likely to develop heart failure (18.5 vs 40%, p<0.01) than RA-ILD patients. In contrast to RA-ILD patients, age adjusted standardised MR was not increased for patients with sarcoidosis and respiratory causes of death significantly less frequent (p<0.01) Conclusion: The hospital-based prevalence of sarcoidosis in WA is higher than previously reported from Australia. Due to lower burden of comorbidity, the overall and respiratory prognosis for sarcoidosis is much better than for RA associated lung disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.